Open AccessRandomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia
Author(s) -
Antonio Arrieta,
John S. Bradley,
Myra W Popejoy,
Mekki Bensaci,
Anjana Grandhi,
Paula M. Bokesch,
Chad Glasser,
Lihong Du,
Hernando Patino,
Nicholas A. Kartsonis
Publication year - 2018
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000001926
Subject(s) - daptomycin , medicine , bacteremia , adverse effect , vancomycin , confidence interval , randomized controlled trial , clinical endpoint , surgery , staphylococcus aureus , antibiotics , biology , bacteria , microbiology and biotechnology , genetics
Staphylococcus aureus, including community-associated methicillin-resistant S. aureus, is an important cause of pediatric bacteremia. Daptomycin is a well-established treatment option for Gram-positive bacteremia in adults, but its safety and efficacy in children require confirmation.